Product Description: Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively[1]. Apilimod is a potent and highly selective PIKfyve inhibitor.
Applications: COVID-19-immunoregulation
Formula: C23H26N6O2
Citations: Biomaterials. 2022 Jun;285:121509./bioRxiv. 2020 Apr 21;2020.04.21.053058. /bioRxiv. 2023 Apr 28./bioRxiv. 2023 Aug 12./bioRxiv. 2023 Aug 28./bioRxiv. 2023 Oct 20:2023.10.19.563158./bioRxiv. 2024 May 10./biorxiv. 2024 May 27./Biotechnol J. 2022 Dec 7;e2200147./Br J Cancer. 2020 Aug;123(4):542-555./Cancer Lett. 2023 Oct 6:216435./Cell Mol Life Sci. 2016 Dec;73(24):4717-4737. /Commun Biol. 2022 Mar 24;5(1):262./Exp Mol Med. 2024 Aug 1./J Biol Chem. 2022 Dec 6;102775./J Virol. 2021 Aug 18;JVI0097521./Mol Biol Cell. 2022 Jan 12;mbcE21060309./Nat Commun. 2020 Mar 27;11(1):1620./PLoS Pathog. 2023 Feb 24;19(2):e1011202./PLoS Pathog. 2025 Jan 2;21(1):e1012800./Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2307423120./Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121./Sci Adv. 2022 Jul 22;8(29):eabn1440./Sci Adv. 2023 Oct 13;9(41):eadh1134./SSRN. 2024 Jan 26./Theranostics. 2020 Mar 4;10(9):3925-3938./Viruses. 2021 Jun 28;13(7):1255./Viruses. 2023 Jun 12, 15(6), 1353./bioRxiv. 2023 Aug 12./bioRxiv. 2024 Jan 23.
References: [1]Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64./[2]Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
CAS Number: 541550-19-0
Molecular Weight: 418.49
Compound Purity: 99.80
Research Area: Inflammation/Immunology; Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Interleukin Related;PIKfyve
Deutsch
English
